RE:RE:RE:Biogen's Aduhelm ... Aduhelm’s approval was so controversial earlier this summer that three members of the FDA’s advisory committee resigned when their near-unanimous decision not to recommend the drug was ignored. The price tag of $56,000 has also been heavily criticised.
It has been reported that the roll-out has been far slower than expected with only around 100 patients receiving the infusion in total. Many clinics have announced that they would not be using Aduhelm, including the Cleveland Clinic and Mount Sinai, with one Washington-DC-based clinic taking the worrying step of banning Biogen reps from the premises.
More attention is also being paid to Aduhelm’s side effects, specially ARIA – amyloid-related imaging abnormalities. The most common form is ARIA-E, a type of cerebral oedema that is associated with headache, confusion, nausea and gait disturbances, among other symptoms.